Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
11.87
+0.03 (0.25%)
At close: Jul 2, 2026, 4:00 PM EDT
11.95
+0.08 (0.67%)
After-hours: Jul 2, 2026, 7:27 PM EDT
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.
Revenue (ttm)
$803.79M
Revenue Growth
+55.61%
P/S Ratio
4.94
Revenue / Employee
$678,880
Employees
1,184
Market Cap
3.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.25% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.89% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 596.96M |
| Arcus Biosciences | 236.00M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Relay Therapeutics | 10.68M |
TLX News
- 2 days ago - Telix Pharma Aligns With FDA To Advance ProstACT Phase 3 Trial Of TLX591-Tx In Prostate Cancer - Nasdaq
- 2 days ago - FDA Alignment to Advance ProstACT Global Phase 3 Trial - GlobeNewsWire
- 5 days ago - Telix Pharmaceuticals Transcript: Status update - Transcripts
- 5 days ago - Telix Pharmaceuticals Slides: Status update - Filings
- 11 days ago - Telix Pharmaceuticals Rises 2.5% as Stock Continues Rebound From Three-Year Low - International Business Times (Australia)
- 12 days ago - Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions - GlobeNewsWire
- 4 weeks ago - Telix Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Telix Pharmaceuticals Transcript: 46th Annual William Blair Growth Stock Conference - Transcripts